Harnessing Hematopoiesis: Creating the Ideal Platform for Large-Scale Expansion of iPSC-Derived, Engineered Hematopoietic Cells

Dr. Valamehr presented Fate Therapeutics’ proprietary iPSC platform, which is designed for the consistent and scalable generation of iPSCs for off-the-shelf therapeutic use. He also reviewed Fate’s proprietary technology for the highly efficient differentiation of genetically-engineered iPSCs into cells of the hematopoietic lineage, including Natural Killer (NK) and T cell-based immunotherapy product candidates.